Share on StockTwits

Alere (NYSE:ALR) CFO Dave Teitel unloaded 10,000 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $35.07, for a total value of $350,700.00. Following the sale, the chief financial officer now directly owns 5,002 shares in the company, valued at approximately $175,420. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Alere (NYSE:ALR) opened at 35.01 on Wednesday. Alere has a 1-year low of $30.14 and a 1-year high of $40.80. The stock’s 50-day moving average is $37.49 and its 200-day moving average is $36.1. The company’s market cap is $2.909 billion.

Alere (NYSE:ALR) last released its earnings data on Monday, August 4th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by $0.16. The company had revenue of $738.30 million for the quarter, compared to the consensus estimate of $747.55 million. During the same quarter in the previous year, the company posted $0.64 earnings per share. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. On average, analysts predict that Alere will post $2.23 earnings per share for the current fiscal year.

A number of research firms have recently commented on ALR. Analysts at Jefferies Group cut their price target on shares of Alere from $45.00 to $40.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann cut their price target on shares of Alere from $40.00 to $38.00 in a research note on Tuesday, August 5th. They now have a “market perform” rating on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of Alere from $50.00 to $45.00 in a research note on Tuesday, August 5th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $42.60.

Alere Inc is a provider of point-of-care diagnostics and services. The Company’s products and services help healthcare practitioners make treatment decisions and improve outcomes for individuals living with chronic disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.